EA200100287A1 - HIGH-AFFINITY ANTIBODIES - Google Patents

HIGH-AFFINITY ANTIBODIES

Info

Publication number
EA200100287A1
EA200100287A1 EA200100287A EA200100287A EA200100287A1 EA 200100287 A1 EA200100287 A1 EA 200100287A1 EA 200100287 A EA200100287 A EA 200100287A EA 200100287 A EA200100287 A EA 200100287A EA 200100287 A1 EA200100287 A1 EA 200100287A1
Authority
EA
Eurasian Patent Office
Prior art keywords
samples
antibody
incubating
hour
sample
Prior art date
Application number
EA200100287A
Other languages
Russian (ru)
Inventor
Питер Джон Харрисон
Original Assignee
Кс Байомедикс Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кс Байомедикс Лтд. filed Critical Кс Байомедикс Лтд.
Publication of EA200100287A1 publication Critical patent/EA200100287A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007Carcino-embryonic Antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Высокоаффинное моноклональное антитело, причем аффинность отличается следующим:(i) инкубацией первого и второго образцов антитела в лунках покрытого антигеном микротитровального планшета при концентрации, выбираемой из пределов участка линейной зависимости в калибровочной кривой, при pH 7,2 в течение 1 ч при 37°C;(ii) удалением несвязанного антитела из обоих образцов;(iii) инкубацией первого образца в ФСБ при pH 7,2 в течение 1 ч при 37°C и снижение pH у второго образца до pH 3 или ниже и инкубацией в течение 1 ч при 37°C;(iv) удалением несвязанного антитела из обоих образцов;(v) инкубацией обоих образцов с конъюгатом анти-антитела и щелочной фосфатазы в течение 1 ч при 37°C;(vi) удалением несвязанного конъюгата из обоих образцов; и(vii) добавлением к образцам субстрата PNPP, измерением поглощения образцов при 405 нм и определением количества антитела, связанного с антигеном, причем связанное количество во втором образце более чем на 50% больше такового в первом образце.Международная заявка была опубликована вместе с отчетом о международном поиске.A high affinity monoclonal antibody, wherein the affinity differs as follows: (i) incubating the first and second antibody samples in the wells of an antigen-coated microtiter plate at a concentration selected from the limits of the linear dependence portion of the calibration curve, at pH 7.2 for 1 hour at 37 ° C (ii) removing unbound antibody from both samples; (iii) incubating the first sample in PBS at pH 7.2 for 1 hour at 37 ° C and lowering the pH of the second sample to pH 3 or below and incubating for 1 hour at 37 ° C; (iv) removing unbound antibody of both samples; (v) incubating both samples with anti-antibody conjugate and alkaline phosphatase for 1 hour at 37 ° C; (vi) removing unbound conjugate from both samples; and (vii) adding PNPP to the substrate samples, measuring the absorbance of the samples at 405 nm and determining the amount of antibody bound to the antigen, with the associated amount in the second sample more than 50% greater than that in the first sample. The international application was published international search.

EA200100287A 1998-08-28 1999-08-20 HIGH-AFFINITY ANTIBODIES EA200100287A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9818915.2A GB9818915D0 (en) 1998-08-28 1998-08-28 Antibodies
PCT/GB1999/002729 WO2000012556A1 (en) 1998-08-28 1999-08-20 High-affinity antibodies

Publications (1)

Publication Number Publication Date
EA200100287A1 true EA200100287A1 (en) 2001-08-27

Family

ID=10838074

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100287A EA200100287A1 (en) 1998-08-28 1999-08-20 HIGH-AFFINITY ANTIBODIES

Country Status (21)

Country Link
EP (1) EP1107990A1 (en)
JP (1) JP2002525082A (en)
KR (1) KR20010089174A (en)
CN (1) CN1315966A (en)
AU (1) AU5435099A (en)
BG (1) BG105294A (en)
BR (1) BR9913303A (en)
CA (1) CA2340865A1 (en)
EA (1) EA200100287A1 (en)
GB (1) GB9818915D0 (en)
HR (1) HRP20010149A2 (en)
HU (1) HUP0103233A3 (en)
ID (1) ID28905A (en)
IL (1) IL141523A0 (en)
MX (1) MXPA01002248A (en)
NO (1) NO20011006D0 (en)
PL (1) PL346472A1 (en)
TR (1) TR200100643T2 (en)
WO (1) WO2000012556A1 (en)
YU (1) YU15401A (en)
ZA (1) ZA200101573B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0031284D0 (en) * 2000-12-21 2001-01-31 Ks Biomedix Ltd High affinity antibodies
GB0112844D0 (en) * 2001-05-25 2001-07-18 Psimei Pharmaceuticals Plc Neutron capture therapy
US20030232401A1 (en) * 2002-06-12 2003-12-18 Pugia Michael J. Bacterial test method by glycated label binding
AU2003256266A1 (en) * 2002-06-12 2003-12-31 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
EP1691763A4 (en) * 2003-12-12 2008-03-12 Genencor Int Cab molecules
CN111848790B (en) * 2020-08-07 2022-02-22 上海交通大学 Bovine-derived single-chain antibody for resisting staphylococcus aureus and preparation and application thereof
CN112724255A (en) * 2021-01-28 2021-04-30 成都金昆生物科技有限公司 Small molecule antibodies targeting carcinoembryonic antigens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5081235A (en) * 1989-07-26 1992-01-14 City Of Hope Chimeric anti-cea antibody
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method

Also Published As

Publication number Publication date
HUP0103233A2 (en) 2001-12-28
CN1315966A (en) 2001-10-03
PL346472A1 (en) 2002-02-11
HRP20010149A2 (en) 2002-02-28
IL141523A0 (en) 2002-03-10
BG105294A (en) 2001-12-29
NO20011006L (en) 2001-02-27
TR200100643T2 (en) 2001-07-23
HUP0103233A3 (en) 2003-10-28
ZA200101573B (en) 2002-02-26
EP1107990A1 (en) 2001-06-20
MXPA01002248A (en) 2002-05-08
NO20011006D0 (en) 2001-02-27
CA2340865A1 (en) 2000-03-09
YU15401A (en) 2003-07-07
GB9818915D0 (en) 1998-10-21
JP2002525082A (en) 2002-08-13
BR9913303A (en) 2001-10-09
ID28905A (en) 2001-07-12
WO2000012556A1 (en) 2000-03-09
KR20010089174A (en) 2001-09-29
AU5435099A (en) 2000-03-21

Similar Documents

Publication Publication Date Title
Hornbeck Enzyme‐linked immunosorbent assays
Hornbeck Enzyme‐linked immunosorbent assays
DK1232392T3 (en) Improved method for detecting acid-resistant bacteria of the genus Helicobacter in feces
DE3751432D1 (en) Immune complex receptors, methods of making them and methods of testing using them.
RU2006145450A (en) ANTIBODY ANALYSIS
Klein-Schneegans et al. Indirect double sandwich ELISA for the specific and quantitative measurement of mouse IgM, IgA and IgG subclasses
Rennard et al. Enzyme linked immunoassay (ELISA) for connective tissue proteins: type I collagen
GB2191577A (en) Layered immunoassay using antibodies bound to transport particles to determine the presence of an antigen
KR900002075A (en) Methods and reagents for specifically binding substances
WO2003046140A3 (en) Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample
ATE320604T1 (en) HOMOGENEOUS DETECTION METHODS FOR DETERMINING SUBPOPULATIONS OF AN ANALYTE
EA200100287A1 (en) HIGH-AFFINITY ANTIBODIES
Alpha et al. Sensitive amplified immunoenzymometric assays (IEMA) for human insulin and intact proinsulin
CN100443897C (en) Multistage enlarging fluoresconce immune analysis method
Mushens et al. Quantitation of monoclonal antibodies by ELISA: The use of purified mouse IgG and mouse IgM monoclonal antibodies as standards in a quantitative ELISA measuring monoclonal antibodies produced by cell culture
CA2434694A1 (en) Detection and quantification of cripto-1
DK0526397T3 (en) Immunological detection method
ES2131279T3 (en) SANDWICH TYPE IMMUNO ASSAY FOR N-PEPTIDE.
Chang et al. Biotin-labeled protein-A enzyme-linked immunosorbent assay for the detection of Japanese encephalitis antibody in sera from humans, swine and several animal species
KR940018099A (en) Methods for Quantifying Antibodies to Mevalonic Acid and Mevalonic Acid
Chang et al. Biotin-labeled antigen sandwich enzyme-linked immunosorbent assay (BLA-S-ELISA) for the detection of Japanese encephalitis antibody in human and a variety of animal sera
KR880701380A (en) Solid phase analysis method
KR880013013A (en) Quantitative reagents and immunochemical methods for the determination of multivalent antigens in liquid samples
ES2076221T3 (en) GEMINAL DERIVATIVES OF DIFENYL AND ITS USE IN IMMUNO ASSAYS.
Halliday et al. A competitive enzyme-immunoassay using labelled antibody